Impact of Previous Coronavirus Disease 2019 on Immune Response After a Single Dose of BNT162b2 Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
María Velasco, ME Alfonso Galán, María Luisa Maestro de las Casas, Elia Pérez‐Fernández, Diana Martínez-Ponce, Beatriz González-Piñeiro, Virgilio Castilla, Carlos Guijarro, Alcorcón COVID-19 Working Group, Alejandro Algora Weber, Juan Carlos Alonso Punter, Gregorio Bonilla Zafra, M. Mercedes Bueno Campaña, Camilo Carrión Pulido, Ana Isabel Díaz Cuasante, Aurora Fabero Jiménez, Rosa María Fariña García, María Isabel González Anglada, M. Mercedes Izquierdo Patron, Susana Lorenzo, Margarita Mosquera González, Montserrat Pérez-Encinas, Elia Pérez‐Fernández, Francisco José Pérez Vega, Renilla Sánchez, María Esther, Ma José Goyanes Galán, Juan Emilio Losa, Gil Rodríguez‐Caravaca
Abstract
Immune response after a single dose of BNT162b2 vaccine was markedly increased in subjects with previous severe acute respiratory syndrome coronavirus 2 infection, reaching similar immunoglobulin titers to those elicited by the full 2 doses in naive cases, and increased modestly after the second dose. These data may inform the priority of the boosting dose.